Balancing Efficacy Outcomes With Tolerability and Quality of Life in First-Line mRCC Treatment Decisions
Panelists discuss how they balance efficacy outcomes like overall survival and progression-free survival against tolerability and quality of life considerations when making decisions about first-line treatment for metastatic renal cell carcinoma patients.
- How do efficacy outcomes, such as overall survival and progression-free survival, compare with tolerability and quality of life in your decision-making process for first-line metastatic renal cell carcinoma treatment?
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
McGregor and Participants Discuss Impact of Drug Efficacy and Histology on nccRCC Care
October 17th 2024During a Case-Based Roundtable® event, Bradley McGregor, MD, moderated a discussion on prognosis and treatment approaches for a patient with stage IV papillary renal cell carcinoma.
Read More
